YOLFTbeta
Cannara Biotech Inc.

Cannara Biotech Inc.

LOVE · TO · Healthcare / Drug Manufacturers - Specialty & Generic

2.03CAD+0.02 (+1.00%)

Price History

Full chart

Market Stats

Previous Close2.01
Open2.02
Day Range2.01 – 2.04
52-Week Range1.55 – 2.37
Volume20.96K
Market Cap211.39M
P/E (TTM)19.45
Forward P/E9.98
EPS0.11
Dividend Yield0.00%
Beta0.36
50-Day Avg1.99
200-Day Avg1.84

About

Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Zohar Krivorot
  • Employees452
  • Headquarters333 Decarie Blvd., Saint-Laurent, QC, Canada, H4N 3M9, Canada
  • Websitehttps://cannara.ca

Leadership

  • Mr. Zohar KrivorotFounder, CEO & Chairman · b. 1977
  • Mr. Nicholas Sosiak C.A., CPAChief Operating Officer
  • Mr. Avi KrivorotChief Technology Officer
  • Mr. Nicholas Fozard CPAChief Financial Officer
  • Mr. Scott CarrollVice President of Investor Relations & Commercial Strategy
  • Mr. Brian ShermanGeneral Counsel & VP Legal Affairs
  • Nick Van DamVice President of Sales
  • Ms. Sabrina SalvoVice President of Marketing
  • Ms. France LandryVice President of Human Resources
  • Etienne LedouxExecutive Officer

Financials

Income Statement

Currency: CAD2018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Total Revenue432.64K2.10M2.55M17.02M35.84M57.26M81.75M107.32M
Growth (%)-+384.70%+21.64%+567.24%+110.58%+59.76%+42.77%+31.28%
Cost of Revenue273.58K403.89K1.33M5.16M19.10M30.03M51.96M60.10M
Gross Profit159.06K1.69M1.22M11.86M16.74M27.23M29.79M47.22M
Gross Margin36.76%80.74%48.00%69.70%46.72%47.56%36.44%44.00%
Operating Expense1.98M11.92M13.15M10.04M12.36M15.34M19.71M25.02M
Operating Income-1.82M-10.22M-11.93M1.82M4.39M11.89M10.08M22.20M
Operating Margin-420.01%-487.52%-467.66%10.71%12.25%20.76%12.33%20.68%
EBITDA-1.68M-10.87M-9.15M4.63M7.85M15.77M15.16M28.18M
EBITDA Margin-388.40%-518.54%-358.62%27.21%21.89%27.54%18.55%26.26%
Net Income-2.41M-13.83M-13.81M-1.53M2.31M6.95M6.44M13.08M
Net Income Margin-556.74%-659.41%-541.32%-8.98%6.43%12.13%7.88%12.18%
R&D--2.60M1.91M1.26M1.03M1.12M711.23K
R&D as % of Total Revenue--101.96%11.20%3.51%1.80%1.37%0.66%
Interest Expense319.93K1.53M1.36M1.73M3.31M5.30M5.66M4.35M
Interest Expense % of Total Revenue73.95%73.05%53.46%10.14%9.25%9.26%6.93%4.06%

Balance Sheet

Currency: CAD2018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Total Assets28.86M68.10M54.85M92.02M125.62M141.52M154.72M168.65M
Total Liabilities14.12M18.17M16.49M27.91M58.88M61.78M66.77M66.43M
Total Equity14.74M47.16M38.36M64.12M66.74M79.74M87.95M102.22M
Cash12.90M26.51M7.77M8.16M12.11M4.27M6.62M14.36M
Total Debt13.03M13.22M12.94M20.90M48.39M45.78M48.33M41.58M
Net Debt126.97K-13.28M5.16M12.74M36.28M41.51M41.71M27.22M

Cash Flow

Currency: CAD2018-08-312019-08-312020-08-312021-08-312022-08-312023-08-312024-08-312025-08-31
Operating Cash Flow-1.15M-7.41M-9.32M-2.09M-6.08M5.91M10.68M20.01M
Investing Cash Flow-14.99M-21.64M-8.55M-30.83M-15.35M-9.48M-5.19M-5.95M
Financing Cash Flow29.04M42.66M-914.82K33.25M25.46M-4.19M-3.14M-6.32M
Capital Expenditure14.99M22.32M8.81M31.07M15.47M9.88M7.47M6.36M
Free Cash Flow-16.14M-29.73M-18.14M-33.17M-21.55M-3.97M3.21M13.65M
Dividends Paid----0000
FCF to OCF1401.02%401.24%194.52%1584.72%354.44%-67.13%30.08%68.23%
Dividend Paid to FCF----0.00%0.00%0.00%0.00%

Earnings

Report DateNov 30, 2025Apr 14, 2026Jul 15, 2026Nov 23, 2026
EPS Estimate0.010.040.040.04
EPS Actual-0.020.04-
Surprise--50.00%0.00%-
Timing-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap211.39M
Enterprise Value224.61M
Trailing P/E19.45
Forward P/E9.98
Price / Sales1.80
Price / Book1.66
EPS0.11
Book Value1.27
Revenue (TTM)117.33M
Gross Profit (TTM)49.97M
EBITDA24.73M
Profit Margin9.25%
Operating Margin23.12%
Return on Equity9.68%
Return on Assets6.26%
Shares Outstanding98.78M
Shares Float45.25M
Beta0.36
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%